-
公开(公告)号:US20230139170A1
公开(公告)日:2023-05-04
申请号:US17930578
申请日:2022-09-08
Applicant: Novartis AG
Inventor: Joseph Paul BULLOCK , Chinmay MAHESHWARI , Quintus MEDLEY , Muneto MOGI , Michela MONTECCHI-PALMER , Kalliopi STASI
IPC: A61K31/517 , A61K47/02 , A61K47/10 , A61K47/26 , A61K47/38
Abstract: The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and methods for treating ocular surface pain by administering such formulations. The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
-
公开(公告)号:US20220162170A1
公开(公告)日:2022-05-26
申请号:US17430819
申请日:2020-02-13
Applicant: Novartis AG
Inventor: Joseph Paul BULLOCK , Chinmay MAHESHWARI , Quintus MEDLEY , Muneto MOGI , Michela MONTECCHI-PALMER , Gregory MORANDI , Michael MUTZ , Kalliopi STASI , Christopher Stephen TOWLER
IPC: C07D239/91
Abstract: The present disclosure provides polymorphs and formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present disclosure further provides methods for treating ocular surface pain by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I). The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
-
公开(公告)号:US20200261457A1
公开(公告)日:2020-08-20
申请号:US16789976
申请日:2020-02-13
Applicant: NOVARTIS AG
Inventor: Joseph Paul BULLOCK , Chinmay MAHESHWARI , Quintus MEDLEY , Muneto MOGI , Michela MONTECCHI-PALMER , Kali STASI
IPC: A61K31/517 , A61K47/38 , A61K47/02 , A61K47/26 , A61K47/10
Abstract: The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and methods for treating ocular surface pain by administering such formulations. The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
-
-